Real-Time Pipeline Data… Beyond the Conference Presentation

Roche presented its late stage pipeline today at JPM20, with tecentriq heading up oncology with six anticipated indications, including expansions in HCC, TNBC, bladdercancer, melanoma, ovariancancer, and NSCLC. In what other indications and patient segments is tecentriq being tested? Kognitic‘s platform makes this information accessible in real-time for clients curious about what is next for this momentum-building asset! See image below for insights into tecentriq’s pipeline.